Sartorius Invests in Biohit

/by

Biohit’s higher operating expenses, including financing costs, have put pressure on its cash position. Cash and cash equivalents have fallen 17% since the beginning of the year to €1.4 million ($2 million).

Helsinki, Finland 8/19/11—Pipette maker Biohit announced that it has arranged a direct issue of new series B shares to Sartorius Lab Holding, corresponding to 4.98% of all Biohit shares. The issue was priced at €2.95 ($4.21 = €0.70 = $1) per share. Biohit stated the action strengthens its financial position and provides for collaboration opportunities with Sartorius.

< | >